Certara's Quarterly Earnings Fall Short of Expectations

Certara (NASDAQ:CERT) released its quarterly earnings results on Wednesday. The company reported earnings of $0.12 per share for the quarter. This figure fell short of analysts' consensus estimate of $0.13 by $0.01, according to Zacks. Certara also reported a negative net margin of 8.34% but a positive return on equity of 3.43%. Additionally, Certara updated its guidance for the fiscal year 2025, expecting earnings per share (EPS) to fall within the range of $0.420 to $0.460.

Certara's Stock Performance

Following the earnings announcement, Certara's stock saw a decrease of 0.4%. The stock price dropped by $0.05 during trading hours, bringing it down to $12.33. On that day, the trading volume was approximately 1,222,313 shares, which is slightly lower than the average volume of 1,274,044 shares. Over the past year, Certara's stock reached a low of $9.41 and a high of $19.87. The company has a 50-day simple moving average of $12.36 and a 200-day simple moving average of $11.63. Certara holds a market capitalization of $1.98 billion, with a price-to-earnings (P/E) ratio of -61.65 and a PEG ratio of 9.29. Additionally, the company maintains a quick ratio and current ratio of 2.86, as well as a debt-to-equity ratio of 0.28.

Market Outlook and Analyst Ratings

Several research firms have recently revised their ratings for Certara. Robert W. Baird lowered their target price for the stock from $18.00 to $13.00 and assigned a "neutral" rating. Similarly, Barclays reduced their price target from $14.00 to $12.00 while maintaining an "equal weight" rating. Presently, six investment analysts have rated the stock as holding and two have given it a buy rating. According to MarketBeat, the average consensus rating for Certara is "Hold," with an average price target set at $15.92.

About Certara

Certara, Inc., along with its subsidiaries, offers software products and technology-driven services focused on biosimulation for drug discovery, preclinical and clinical research, regulatory submissions, and market access, both domestically and globally. The company provides solutions that facilitate model-informed drug development and employ biosimulation techniques to forecast pharmacokinetics and pharmacodynamics.

Certara, Earnings, Stock